Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 216

Similar articles for PubMed (Select 23910030)

1.

Prevention of meningococcal infections in the first 2 years of life.

Woods CR.

Pediatr Ann. 2013 Aug;42(8):164-71. doi: 10.3928/00904481-20130723-11. Review.

PMID:
23910030
2.

Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE; Centers for Disease Control and Prevention (CDC).

MMWR Recomm Rep. 2013 Mar 22;62(RR-2):1-28.

3.

Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2013 Jan 25;62(3):52-4.

4.

Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™).

Croxtall JD, Dhillon S.

Drugs. 2012 Dec 24;72(18):2407-30. doi: 10.2165/11209580-000000000-00000. Review.

PMID:
23231026
5.

Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013.

MacNeil JR, Rubin L, McNamara L, Briere EC, Clark TA, Cohn AC; Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC.

MMWR Morb Mortal Wkly Rep. 2014 Jun 20;63(24):527-30.

6.

MenACWY-TT vaccine for active immunization against invasive meningococcal disease.

Papaevangelou V, Spyridis N.

Expert Rev Vaccines. 2012 May;11(5):523-37. doi: 10.1586/erv.12.32. Review.

PMID:
22827239
7.

Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States.

Lingappa JR, Rosenstein N, Zell ER, Shutt KA, Schuchat A, Perkins BA; Active Bacterial Core surveillance (ABCs) team.

Vaccine. 2001 Aug 14;19(31):4566-75.

PMID:
11483285
8.

Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.

Shepard CW, Ortega-Sanchez IR, Scott RD 2nd, Rosenstein NE; ABCs Team.

Pediatrics. 2005 May;115(5):1220-32.

PMID:
15867028
9.

Meningococcal vaccine evolution.

Bona G, Guidi C.

J Prev Med Hyg. 2012 Sep;53(3):131-5.

PMID:
23362617
10.

Meningococcal disease and vaccination in North America.

Pollard AJ, Scheifele D.

J Paediatr Child Health. 2001 Oct;37(5):S20-7.

PMID:
11885732
11.

Prospects for vaccine prevention of meningococcal infection.

Harrison LH.

Clin Microbiol Rev. 2006 Jan;19(1):142-64. Review.

12.

Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.

Caro JJ, Möller J, Getsios D, Coudeville L, El-Hadi W, Chevat C, Nguyen VH, Caro I.

BMC Public Health. 2007 Jun 29;7:130.

13.

Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy.

Bechini A, Levi M, Boccalini S, Tiscione E, Ceccherini V, Taddei C, Balocchini E, Bonanni P.

J Prev Med Hyg. 2012 Jun;53(2):61-7.

PMID:
23240162
14.

Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra.

Reisinger KS, Baxter R, Block SL, Shah J, Bedell L, Dull PM.

Clin Vaccine Immunol. 2009 Dec;16(12):1810-5. doi: 10.1128/CVI.00207-09. Epub 2009 Oct 7.

15.

Optimizing protection against meningococcal disease.

Reisinger KS, Black S, Stoddard JJ.

Clin Pediatr (Phila). 2010 Jun;49(6):586-97. doi: 10.1177/0009922809354327. Epub 2010 Jan 20. Review.

PMID:
20089551
16.

Vaccines for the prevention of meningococcal disease in children.

Soriano-Gabarró M, Stuart JM, Rosenstein NE.

Semin Pediatr Infect Dis. 2002 Jul;13(3):182-9. Review.

PMID:
12199614
17.

[Meningococcal vaccines: from polysaccharide to conjugate vaccines].

Cohen R, Levy C.

Arch Pediatr. 2012 Sep;19 Suppl 2:S61-4. doi: 10.1016/S0929-693X(12)71275-7. French.

PMID:
22883368
18.

Meningococcal disease before and after the introduction of meningococcal serogroup C conjugate vaccine. Federal District, Brazil.

Tauil Mde C, Carvalho CS, Vieira AC, Waldman EA.

Braz J Infect Dis. 2014 Jul-Aug;18(4):379-86. doi: 10.1016/j.bjid.2013.11.012. Epub 2014 Mar 31.

19.

Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.

Perrett KP, Snape MD, Ford KJ, John TM, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ.

Pediatr Infect Dis J. 2009 Mar;28(3):186-93. doi: 10.1097/INF.0b013e31818e037d.

PMID:
19209097
20.

Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.

Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, Dull PM; V59P13 Study Group.

Clin Infect Dis. 2009 Jul 1;49(1):e1-10. doi: 10.1086/599117.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk